Abstract Number: 2503 • 2014 ACR/ARHP Annual Meeting
Early Response to Full-Dose Etanercept-Plus-Methotrexate Induction Therapy Predicts Sustained Remission with Reduced-Dose Combination Therapy in Early Rheumatoid Arthritis Patients
Background/Purpose: In early rheumatoid arthritis (RA), achievement of clinical remission and low disease activity (LDA) limits joint damage and disability.1 Anti-TNF agents are effective in…Abstract Number: 1601 • 2014 ACR/ARHP Annual Meeting
Are There Gender Specific Differences in Patient Characteristics at Initiation of Biologic Treatment in Ankylosing Spondylitis and Psoriatic Arthritis?
Background/Purpose The prevalence of ankylosing spondylitis (AS) is 2-3 times higher in men compared to women whereas psoriatic arthritis (PsA) is generally considered a disease…Abstract Number: 1143 • 2014 ACR/ARHP Annual Meeting
Preferences of Biologic Treatment Characteristics Among Rheumatoid Arthritis Patients Who Are Current Biologic Therapy Users
Background/Purpose: To identify the most and least important characteristics of rheumatoid arthritis (RA) treatment according to patients currently on biologic therapy. Methods: From the HealthCore…Abstract Number: 493 • 2014 ACR/ARHP Annual Meeting
Efficacy and Safety of Tofacitinib Following Inadequate Response to Nonbiologic DMARD or Biologic DMARD
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Here we compare the efficacy and safety of tofacitinib 5…Abstract Number: 2497 • 2014 ACR/ARHP Annual Meeting
Correlation Between Time to Switch and Clinical Response Amplitude to Rituximab in Second Line Treatment in Rheumatoid Arthritis Patients with Treatment Failure to Tumor Necrosis Factor Inhibitors: 3-Year Data from Repeat Observational Study
Background/Purpose: In recent years we assist to an increasing interest to get more clinical data to improve the control of disease course in rheumatoid arthritis…Abstract Number: 1569 • 2014 ACR/ARHP Annual Meeting
Persistence of Biologic Therapy in Psoriatic Disease: Results from the Psoriasis Longitudinal Assessment and Registry
Background/Purpose We evaluated persistency (treatment longevity) of biologics in patients (pts) with psoriasis (PsO), as well as with psoriatic arthritis (PsA) in the context of…Abstract Number: 1142 • 2014 ACR/ARHP Annual Meeting
Healthcare Costs Associated with Serious Infections Among Biologic-Naïve Rheumatoid Arthritis Patients Initiating First-Line Biologic Treatment
Background/Purpose: The risk of serious infections can vary across biologics. For example, in the 2-year AMPLE trial, serious infections occurred in 3.8% of SC abatacept-treated…Abstract Number: 125 • 2014 ACR/ARHP Annual Meeting
PD Signal Detected By Ultrasonography Relates to Joint Destruction in Rheumatoid Arthritis Under Biologics Therapy in Real World
Background/Purpose: Biologic DMARD (biologics) therapy for rheumatoid arthritis (RA) strongly suppresses joint destruction regardless of its efficacy for disease activity. On the contrary power Doppler…Abstract Number: 2491 • 2014 ACR/ARHP Annual Meeting
Prognostic Factors for IV Abatacept Retention in Patients Who Have Received at Least One Prior Biologic Agent: 2-Year Results from a Prospective, International, Real-World Study
Background/Purpose: To identify prognostic factors of retention for abatacept (ABA) treatment in patients (pts) with moderate-to-severe RA, using final results from the real-world ACTION study.…Abstract Number: 1555 • 2014 ACR/ARHP Annual Meeting
An Indirect Comparison and Cost per Responder Analysis of Adalimumab, Methotrexate (MTX) and Apremilast in the Treatment of MTX-naïve Psoriatic Arthritis (PsA) Patients
Background/Purpose: Apremilast (APR), a small molecule inhibitor of phospodiesterase 4 (PDE-4), was recently approved for treating PsA patients in the US. To date, there are…Abstract Number: 1067 • 2014 ACR/ARHP Annual Meeting
Mortality Trends in Rheumatoid Arthritis during the Biologic Era, 1998 to 2011
Background/Purpose: Rheumatoid arthritis (RA) has consistently been associated with increased mortality risk, a risk that appears to be linked with greater disease activity. Although there…Abstract Number: 97 • 2014 ACR/ARHP Annual Meeting
Identification of Tuberculosis in Rheumatoid Arthritis Patients Initiating Therapy with Biologic or Non-Biologic Disease-Modifying Anti-Rheumatic Drugs Using Health Insurance Claims Data
Background/Purpose: Biologic DMARDs used for the treatment of RA may increase the risk of tuberculosis (TB).1 Large healthcare claims databases are useful in assessing rare…Abstract Number: 2481 • 2014 ACR/ARHP Annual Meeting
Which Factors Influence the Prescription of Tocilizumab Alone or in Combination with DMARDs in Rheumatoid Arthritis Patients in a Real Life Setting?: An Interim Analysis of Safety and Efficacy at 6 Months
Background/Purpose Baseline factors influencing the use of tocilizumab (TCZ) in monotherapy (Mono) instead of combination with DMARDs (Combo) in real-life practice in RA patients (pts)…Abstract Number: 1559 • 2014 ACR/ARHP Annual Meeting
Long Term Improvements in Physical Function Are Associated with Improvements in Dactylitis, Enthesitis, Tender and Swollen Joint Counts, and Psoriasis Skin Involvement: Results from a Phase 3 Study of Ustekinumab in Psoriatic Arthritis Patients
Background/Purpose: To evaluate the association of improvements in tender and swollen joint counts (TJC, SJC), psoriasis skin involvement, and dactylitis/enthesitis (in patients affected at baseline)…Abstract Number: 1060 • 2014 ACR/ARHP Annual Meeting
Musculoskeletal Surgeries and Procedures in Patients with RA: Results from a UK Retrospective Study
Background/Purpose: Musculoskeletal surgeries and procedures substantially improve the quality of life of patients with RA, but represent an important burden in terms of medical costs.…
- « Previous Page
- 1
- …
- 21
- 22
- 23
- 24
- 25
- …
- 29
- Next Page »